Par Drugs and Chemicals (NSE:PAR) Total Current Liabilities: ₹137 Mil (As of Mar. 2026)


NSE:PAR Par Drugs and Chemicals Ltd NSE:PAR
79 GF Score
Price ₹88.89
GF Value ₹207.83
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Par Drugs and Chemicals Total Current Liabilities?

Par Drugs and Chemicals NSE:PAR -2.84% 79 Total Current Liabilities is ₹137 Mil as of Mar. 2026. GuruFocus rates NSE:PAR with a GF Score™ of 79/100 and a GF Value™ of ₹207.83 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Par Drugs and Chemicals's total current liabilities for the quarter that ended in Mar. 2026 was ₹137

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Par Drugs and Chemicals Total Current Liabilities Related Terms

Par Drugs and Chemicals Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Par Drugs and Chemicals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Par Drugs and Chemicals Total Current Liabilities Chart

Par Drugs and Chemicals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.57 139.89 124.39 165.69 137.44

Par Drugs and Chemicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.69 0.00 0.00 0.00 137.44
NSE:PAR
79GF Score
Par Drugs and Chemicals Ltd NSE:PAR
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Par Drugs and Chemicals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Par Drugs and Chemicals's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=81.939+0
+Other Current Liabilities+Current Deferred Liabilities
=55.497+0
=137

Par Drugs and Chemicals's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=81.939+0
+Other Current Liabilities+Current Deferred Liabilities
=55.497+0
=137

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of ₹137 Mil mean?
Par Drugs and Chemicals (NSE:PAR) has a Total Current Liabilities of ₹137 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Par Drugs and Chemicals and its competitors.
Is Par Drugs and Chemicals' Total Current Liabilities too high?
Par Drugs and Chemicals' current Total Current Liabilities is ₹137 Mil. Overall, Par Drugs and Chemicals has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' Total Current Liabilities compare to ZTS and UTHR?
Par Drugs and Chemicals' Total Current Liabilities of ₹137 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Par Drugs and Chemicals and its competitors. Par Drugs and Chemicals's current Total Current Liabilities is ₹137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.83, compared to a current price of ₹88.89 — trading 57.2% below its estimated fair value. The current Total Current Liabilities is ₹137 Mil. Par Drugs and Chemicals' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current Total Current Liabilities is ₹137 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?

Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued. The current stock price of ₹88.89 is trading 57.2% below its estimated GF Value™ of ₹207.83. GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.

Key valuation signals for NSE:PAR:

  • Total Current Liabilities: ₹137 Mil
  • GF Value™: ₹207.83 vs. price of ₹88.89 (57.2% below fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Par Drugs and Chemicals Business Description

Address Gotri Vasna Road, 815, Nilamber Triumph, Vadodara, GJ, IND, 390007
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
79GF Score

Get the complete analysis for NSE:PAR

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹88.89
Price
₹207.83
GF Value